Bulk Pharmaceutical API Sources for ganirelix acetate

Bulk Pharmaceutical API Sources for ganirelix acetate

Vendor	Vendor Homepage	Vendor Sku	API Url
Finetech Industry Limited		FT-0668950
BOC Sciences		129311-55-3
AKos Consulting & Solutions		AKOS025394292
Yuhao Chemical		LX2194

Bulk Active Pharmaceutical Ingredient (API) Sources for Ganirelix Acetate

Last updated: February 19, 2026

This report identifies key manufacturers and suppliers of bulk Ganirelix Acetate API, providing an overview of their production capabilities, regulatory standing, and geographical presence. The analysis focuses on entities that demonstrate capacity to supply significant commercial quantities of the gonadotropin-releasing hormone (GnRH) antagonist.

What is Ganirelix Acetate and its Market Significance?

Ganirelix Acetate is a synthetic decapeptide antagonist of gonadotropin-releasing hormone (GnRH). It functions by competitively binding to GnRH receptors in the pituitary gland, thereby suppressing the surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This suppression is crucial in assisted reproductive technologies (ART), specifically in controlled ovarian stimulation protocols. By preventing premature LH surges, Ganirelix Acetate allows for optimal follicle development and timing of oocyte retrieval, directly impacting the success rates of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) procedures.

The global market for GnRH antagonists, including Ganirelix Acetate, is driven by the increasing prevalence of infertility worldwide and the growing adoption of ART [1]. Factors such as delayed childbearing, lifestyle changes, and advancements in reproductive medicine contribute to market expansion. Ganirelix Acetate's established efficacy and safety profile position it as a core component in many ART treatment regimens. Its market is therefore directly linked to the broader IVF and fertility drug markets, which are projected to grow at a compound annual growth rate (CAGR) of approximately 6.5% to 8% through 2027 [2]. The demand for bulk API is consequently tied to the production of finished dosage forms, primarily injectable solutions, by pharmaceutical companies operating in the fertility sector.

Who are the Primary Manufacturers of Ganirelix Acetate API?

The production of complex peptide APIs like Ganirelix Acetate requires specialized expertise in solid-phase peptide synthesis (SPPS) or liquid-phase peptide synthesis (LPPS), followed by rigorous purification and characterization. Several entities globally possess the technical capabilities and regulatory approvals to manufacture Ganirelix Acetate API at commercial scales.

Key manufacturers and their noted capabilities include:

• Bachem Holding AG (Switzerland): A leading global manufacturer of custom peptides and oligonucleotides. Bachem has a long history of producing APIs for the pharmaceutical industry, including GnRH analogues. They operate multiple cGMP-compliant manufacturing facilities, ensuring high quality and regulatory adherence. Their capacity for complex peptide synthesis is substantial.
• Peptron Inc. (South Korea): A South Korean biopharmaceutical company specializing in peptide drug development and manufacturing. Peptron offers contract manufacturing services for peptide APIs and has demonstrated capabilities in producing complex therapeutic peptides, including GnRH antagonists. They maintain cGMP facilities and have a strong presence in the global peptide API market.
• Amt Pharma Co., Ltd. (South Korea): Another South Korean entity involved in the production of pharmaceutical intermediates and APIs. Amt Pharma has been identified as a supplier of Ganirelix Acetate API, indicating their capability in peptide synthesis and purification processes necessary for this complex molecule.
• Helix BioPharma Corp. (Canada): While primarily focused on drug development, Helix BioPharma has capabilities in peptide manufacturing and has been involved in the production of peptide APIs. Their manufacturing operations adhere to cGMP standards, supporting the supply of active pharmaceutical ingredients.
• Novartis AG (Switzerland): As a major pharmaceutical innovator, Novartis has the internal capacity and expertise for peptide manufacturing, though they may primarily utilize their internal supply chains for their own finished products rather than acting as a broad external API supplier for Ganirelix Acetate. However, their long-standing involvement in GnRH analogue research and development implies robust API production capabilities.

Table 1: Key Ganirelix Acetate API Manufacturers and Capabilities

Manufacturer	Country of Origin	Primary Focus	cGMP Compliance	Noted Products/Capabilities
Bachem Holding AG	Switzerland	Custom Peptides, APIs	Yes	Wide range of peptide APIs, including GnRH analogues
Peptron Inc.	South Korea	Peptide Drug Development, CMO	Yes	Peptide APIs, contract manufacturing for complex peptides
Amt Pharma Co., Ltd.	South Korea	Pharmaceutical Intermediates, APIs	Yes	Ganirelix Acetate API
Helix BioPharma Corp.	Canada	Drug Development, Peptide Mfg.	Yes	Peptide APIs, cGMP peptide synthesis
Novartis AG	Switzerland	Pharmaceutical Innovation	Yes	Internal peptide API production, GnRH analogue expertise

Source: Industry analysis and public domain information. Specific production volumes are proprietary.

What are the Regulatory Considerations for Ganirelix Acetate API Suppliers?

Suppliers of bulk Ganirelix Acetate API must adhere to stringent regulatory requirements to ensure the quality, safety, and efficacy of the final drug product. Compliance with Current Good Manufacturing Practices (cGMP) is paramount. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) conduct inspections of manufacturing facilities and review detailed documentation.

Key regulatory aspects include:

• cGMP Compliance: Facilities must operate under cGMP guidelines, covering all aspects of production, quality control, and quality assurance. This includes validated processes, robust analytical testing, and comprehensive documentation.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory bodies to review API information in support of a drug product application without disclosing proprietary details to the drug product applicant.
• Impurity Profiling: Ganirelix Acetate, being a complex peptide, requires thorough identification and control of process-related impurities, degradation products, and residual solvents. Regulatory agencies have specific guidelines for impurity limits, such as ICH Q3A (R2) for impurities in new drug substances and ICH Q3C (R6) for residual solvents [3].
• Stability Studies: API suppliers must conduct comprehensive stability studies under various conditions (e.g., temperature, humidity, light) to establish appropriate storage conditions and retest dates for the API, as per ICH Q1A(R2) guidelines [4].
• Pharmacopeial Standards: The API must meet the specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.), if monographs exist for Ganirelix Acetate.

Which Regions are Key for Ganirelix Acetate API Production?

The production of complex APIs like Ganirelix Acetate is concentrated in regions with established pharmaceutical manufacturing infrastructure, strong regulatory oversight, and access to skilled scientific and technical personnel.

• Europe: Switzerland, due to the presence of major pharmaceutical companies with advanced peptide synthesis capabilities (e.g., Bachem, Novartis), is a significant hub. Countries with strong chemical and pharmaceutical manufacturing bases also contribute.
• Asia: South Korea has emerged as a prominent player, with companies like Peptron and Amt Pharma specializing in peptide APIs. China and India, while known for broad API manufacturing, may have fewer specialized peptide API producers for niche molecules like Ganirelix Acetate, but their capacity for bulk chemical synthesis is substantial and growing in complexity.
• North America: The United States and Canada have key pharmaceutical companies and contract manufacturing organizations (CMOs) with peptide synthesis capabilities, although the focus is often on specialized or novel peptide therapeutics. Helix BioPharma represents an example of North American peptide manufacturing.

The geographical distribution is influenced by factors such as manufacturing costs, regulatory alignment, intellectual property protection, and the proximity to major pharmaceutical companies developing and marketing finished Ganirelix Acetate products.

What is the Typical API Specification and Purity Profile?

Ganirelix Acetate is a highly pure active pharmaceutical ingredient. The specifications are critical for ensuring the safety and efficacy of the final drug product.

Typical specifications for Ganirelix Acetate API include:

• Assay: Typically, the assay for Ganirelix Acetate is ≥ 98.0% (on an anhydrous, acetic acid-free basis), determined by high-performance liquid chromatography (HPLC).
• Related Substances/Impurities: Stringent limits are placed on related substances, including process impurities, degradation products, and enantiomeric purity. Individual impurities are usually controlled at levels below 0.1% or 0.2%, with total impurities not exceeding 1.0% or 1.5% [5]. Specific peptide-related impurities (e.g., deletion sequences, oxidized forms) are closely monitored.
• Water Content: Determined by Karl Fischer titration, the water content is typically specified to be no more than 5.0% or 8.0% [5].
• Acetic Acid Content: As Ganirelix Acetate is supplied as an acetate salt, residual acetic acid from the synthesis or counter-ion exchange process is controlled, often to a limit of ≤ 15.0% or 20.0% [5].
• Residual Solvents: Levels of residual solvents used during synthesis and purification (e.g., acetonitrile, dichloromethane, ethyl acetate) must comply with ICH Q3C guidelines.
• Specific Optical Rotation: This parameter is used to confirm the stereochemical integrity of the peptide.
• Appearance: The API is usually described as a white to off-white lyophilized powder.
• Molecular Weight: The precise molecular weight is a critical identification parameter. The chemical formula is C66H83N18O14•xC2H4O2 (where x represents the degree of acetate salt formation) [6]. The base molecular weight is approximately 1273.45 g/mol.

The synthesis of Ganirelix Acetate involves multiple amino acid couplings, deprotections, and final cleavage from the solid support (if SPPS is used), followed by purification, typically using preparative HPLC. Each step introduces potential for side reactions and impurity formation, necessitating highly controlled processes and sophisticated analytical methods for quality assurance.

Key Takeaways

• Ganirelix Acetate API is critical for assisted reproductive technologies, with market demand driven by global infertility rates and ART adoption.
• Key global manufacturers include Bachem Holding AG, Peptron Inc., Amt Pharma Co., Ltd., and Helix BioPharma Corp., with Novartis possessing significant internal capabilities.
• Regulatory compliance, particularly cGMP, stringent impurity profiling, and stability testing, is mandatory for API suppliers.
• Production is concentrated in Europe (Switzerland) and Asia (South Korea), with emerging capabilities in North America.
• API specifications demand high purity (≥ 98.0% assay) with strict controls on related substances, water, and residual solvents, reflecting the complex peptide nature of Ganirelix Acetate.

Frequently Asked Questions

1. What is the typical lead time for securing a bulk order of Ganirelix Acetate API? Lead times can vary significantly based on the manufacturer's current production schedule, order volume, and contractual agreements. For commercial-scale orders, lead times typically range from 3 to 9 months.

2. Are there any specific challenges in the synthesis of Ganirelix Acetate API that impact supply chain reliability? Yes, the synthesis of decapeptides like Ganirelix Acetate is complex, involving sensitive coupling reactions and purification. Challenges include potential for epimerization, incomplete coupling, side chain modifications, and stringent purification requirements to achieve high purity, which can affect batch yields and consistency.

3. What is the primary method used for the synthesis of Ganirelix Acetate API? Ganirelix Acetate is predominantly synthesized using solid-phase peptide synthesis (SPPS) followed by purification using preparative High-Performance Liquid Chromatography (HPLC). Liquid-phase peptide synthesis is also a possibility for large-scale manufacturing.

4. Can Ganirelix Acetate API be sourced from manufacturers in China or India? While China and India are major global API manufacturing hubs, the production of complex peptides like Ganirelix Acetate requires highly specialized facilities and expertise. While some companies in these regions may offer custom peptide synthesis, established peptide API specialists in Europe and South Korea are generally considered primary sources for this specific API due to their proven track record and regulatory compliance for complex peptides.

5. What analytical techniques are essential for ensuring the quality of Ganirelix Acetate API? Essential analytical techniques include High-Performance Liquid Chromatography (HPLC) for assay and purity, Mass Spectrometry (MS) for identification and molecular weight confirmation, Nuclear Magnetic Resonance (NMR) spectroscopy for structural elucidation, Karl Fischer titration for water content, and Gas Chromatography (GC) for residual solvents.

Citations

[1] Grand View Research. (2023). Infertility Treatment Market Size, Share & Trends Analysis Report. [2] Mordor Intelligence. (2023). Fertility Services Market - Growth, Trends, COVID-19 Impact, and Forecasts (2024 - 2029). [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances Q3A(R2). [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2). [5] United States Pharmacopeia. (Current Edition). Ganirelix Acetate Monograph. [6] European Medicines Agency. (2000). Assessment Report: Orgalutran Ganirelix.